Diabetes

Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.

Top news of the day from across the health care landscape.

Dapagliflozin is a selective sodium‑glucose cotransporter-2 (SGLT-2) inhibitor that is combined with a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, saxagliptin; and metformin hydrochloride extended release.

Officials with the FDA have approved AstraZeneca’s dapagliflozin, saxagliptin and metformin hydrochloride (Qternmet XR) extended release tablets for adults with type 2 diabetes.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Novo Nordisk announced the results of the ELLIPSE trial, which examined efficacy and safety and demonstrated superiority of liraglutide (Victoza) injection 1.8 mg vs placebo, in a presentation at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, MD, on Sunday.

Manufacturers file challenge in court resulting in compromise between state government and pharmaceutical companies.

Antioxidants can be used to improve certain health conditions.

Top news of the day from across the health care landscape.

They cover considerations for planning and executing strategies for patients and coordinating MTM with local pharmacies.

A study, which tested naturally occurring homoisoflavonoids found in the Hyacinthaceae plant family and their synthetic derivatives, focused on the abnormal growth of new blood vessel cells in the eye that are linked to types of blindness.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The expansion of the Valyou Savings Program helps to address the challenge many patients face regarding unpredictable and unaffordable pricing for their insulin, according to the company.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The hearing will take place May 13, 2019 at the agency’s headquarters in Silver Spring, Maryland.

If approved, Gimoti would be the first non-oral drug treatment for symptoms associated with acute and recurrent diabetic gastroparesis in adult women and would represent the first significant advancement in the treatment of gastroparesis in 40 years.

Of the 81 metrics included in the Healthiest Communities analysis, diabetes prevalence and smoking rate have the strongest correlation to life expectancy.

Although generic versions of prescription medications can be a cheaper alternative for patients, many perceive generics as less effective and less safe than their brand-name counterparts.

Pharmacists can offer important counseling points on the appropriate use of the devices to monitor blood glucose levels at home.

Pharmacists can offer important counseling points on the appropriate use of the devices to monitor blood glucose levels at home.

Hello and welcome to the Pharmacy Times News Network. I’m Nicole Grassano your host for our Pharmacy Week in Review.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more.

Semaglutide offers a non-insulin solution that, in combination with healthy diet and exercise, may improve blood sugar.